Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of XEN901 in Healthy Subjects
NCT03467100Phase 1Completed
- Sponsor
- Xenon Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy, SCN8A-related epilepsy with encephalopathy (EIEE13) and focal onset seizure comparing XEN901 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events, Resting 12-lead electrocardiogram and 1 more. Started Feb 2018; status: completed.
02
Drugs
zandatrigine
03
Conditions
epilepsySCN8A-related epilepsy with encephalopathy (EIEE13)focal onset seizure
Beyond the preview
Go deeper on NCT03467100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467100.